Press release
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
Webcast and Conference Call To be Held Wednesday November 24, 2021, 4:30 pm EDT NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Webcast and Conference Call To be Held Wednesday November 24, 2021, 4:30 pm EDT\nNEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2021 on Wednesday November 24, 2021. Management will host a conference call on Wednesday November 24, 2021, at 4:30 pm EDT to review financial results and describe the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session. Webcast / Conference Call Information: The live webcast of the conference call can be accessed online at https://wsw.com/webcast/cc/avxl20/1492110. To join the conference call, live via telephone, interested parties within the U.S. should dial, toll-free, 1 (866) 939-3921 and international callers should dial 1 (678) 302-3550. Please use confirmation number 50258076, followed by the pound sign (#). A replay of the conference call will also be available on www.anavex.com. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat...